Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma.

Br J Cancer · 2023 · PMC10646009 · PMID 37723317

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Comparison of the response to BH3-mimetics in the CHLA15 and CHLA20 cells demonstrates a marked and highly significant loss of sensitivity to BCL2 and BCL-X L inhibition, as evidenced by the resistance to ABT199 and A1331852 in the CHLA20 cells (Fig. 2 b).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.